Position in ANAB
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$387,180
+$44,771 QoQ
Shares Held
5,736
-38.1% QoQ
Ownership
0.020%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#124
of 211 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 59%
Shared 31%
None 10%
Common Shares in ANAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Savant Capital, LLC holds $23,538,035 across 24 Biotechnology names. ANAB ranks #10 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
26,241 | $13,034,691 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,687 | $2,298,991 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
4,776 | $1,150,872 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
12,479 | $929,435 | |
| 5 | RPRX |
Royalty Pharma plc
|
16,059 | $900,428 | |
| 6 | CORT |
Corcept Therapeutics Inc
|
6,935 | $602,998 | |
| 7 | IONS |
Ionis Pharmaceuticals Inc
|
7,476 | $592,772 | |
| 8 | MRNA |
Moderna, Inc.
|
7,432 | $520,462 |
All Filings in ANAB
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $387,180 | 5,736 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $342,409 | 6,174 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $305,181 | 6,295 | Shares | Sole | 2026-02-10 | |
| No filing history on record for this holder in this stock. | ||||||